We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) ended the recent trading session at $46.93, demonstrating a -1.59% change from the preceding day's closing price. This change lagged the S&P 500's 0.28% loss on the day. Meanwhile, the Dow lost 0.44%, and the Nasdaq, a tech-heavy index, lost 0.28%.
The company's stock has dropped by 10.89% in the past month, falling short of the Medical sector's loss of 7.53% and the S&P 500's loss of 3.59%.
The investment community will be paying close attention to the earnings performance of CRISPR Therapeutics AG in its upcoming release. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.15 per share, which would represent year-over-year growth of 27.22%. At the same time, our most recent consensus estimate is projecting a revenue of $7.32 million, reflecting a 741.03% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$4.85 per share and a revenue of $39.15 million, signifying shifts of +25.04% and +1015.33%, respectively, from the last year.
Any recent changes to analyst estimates for CRISPR Therapeutics AG should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.87% higher. CRISPR Therapeutics AG is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 142, placing it within the bottom 43% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note
CRISPR Therapeutics AG (CRSP - Free Report) ended the recent trading session at $46.93, demonstrating a -1.59% change from the preceding day's closing price. This change lagged the S&P 500's 0.28% loss on the day. Meanwhile, the Dow lost 0.44%, and the Nasdaq, a tech-heavy index, lost 0.28%.
The company's stock has dropped by 10.89% in the past month, falling short of the Medical sector's loss of 7.53% and the S&P 500's loss of 3.59%.
The investment community will be paying close attention to the earnings performance of CRISPR Therapeutics AG in its upcoming release. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.15 per share, which would represent year-over-year growth of 27.22%. At the same time, our most recent consensus estimate is projecting a revenue of $7.32 million, reflecting a 741.03% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$4.85 per share and a revenue of $39.15 million, signifying shifts of +25.04% and +1015.33%, respectively, from the last year.
Any recent changes to analyst estimates for CRISPR Therapeutics AG should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.87% higher. CRISPR Therapeutics AG is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 142, placing it within the bottom 43% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.